New Delhi, 22 Aug (EFE).-the Supreme Court of India was postponed today until September the beginning of the trial that pits the multinational pharmaceutical Novartis with manufacturers of generics of the Asian giant, told Efe a source from the company.

“there has been no view today. has been postponed to September 11”, explained EfE spokesman for Novartis in India Svetlana Pinto.

the trial, which was scheduled to start today, must be resolved if he is granted a patent in India to the anti-cancer drug Glivec multinational, currently replaced by Indian versions in the market much more cheap.

analysts believe that a ruling favorable to Novartis could have a domino effect in other similar disputes and jeopardize the India to continue to be the main supplier of generic drugs in the world, especially to developing countries.

the India left in 1970 to grant patents on medicines, but the law was amended in 2005 in compliance with the rules of the World Trade Organization (WTO), of which the Asian giant is a State member.

New Delhi was then opened to admit drug registration but it established the merit of the patent on the basis that the drug submit an innovation significant.

in the case of Novartis, which has six years immersed in a court in the India, battle different courts in the Asian country have considered that its anti-cancer drug does not represent an innovation, and therefore the multinational resorted to the Supreme Court.

in 2006, when the India rejected the patent of the multinational (marketed as Gleevec or Glivec) imatinib mesylate, the Novartis drug cost $2,600 per patient per month, and the Indian generic versions only $200.

according to Artsen zonder grenzen (AZG), “als Novartis het geval wint verleend zijn andere octrooien als in de krachtige landen” en “De India zou niet zitten kundig voor blijven leveren veel van de onderontwikkelde wereld kwaliteit betaalbare geneesmiddelen”.

80% van de medicijnen gebruikt Artsen zonder grenzen (AZG) voor de behandeling van 170.000 mensen met het virus van AIDS in de wereld generieke Indische zijn. EFE